JP2006528182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528182A5 JP2006528182A5 JP2006521149A JP2006521149A JP2006528182A5 JP 2006528182 A5 JP2006528182 A5 JP 2006528182A5 JP 2006521149 A JP2006521149 A JP 2006521149A JP 2006521149 A JP2006521149 A JP 2006521149A JP 2006528182 A5 JP2006528182 A5 JP 2006528182A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- segment
- suspension
- minutes
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000725 suspension Substances 0.000 description 28
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 229940126409 proton pump inhibitor Drugs 0.000 description 17
- 239000000612 proton pump inhibitor Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000008238 pharmaceutical water Substances 0.000 description 5
- -1 dontoprazole Chemical compound 0.000 description 3
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960004157 rabeprazole Drugs 0.000 description 2
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
- CMZHQFXXAAIBKE-UHFFFAOYSA-N 5'-hydroxyomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(CO)C(OC)=C1C CMZHQFXXAAIBKE-UHFFFAOYSA-N 0.000 description 1
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229950007395 leminoprazole Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229950008375 tenatoprazole Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48832403P | 2003-07-18 | 2003-07-18 | |
| PCT/US2004/023044 WO2005007117A2 (en) | 2003-07-18 | 2004-07-16 | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006528182A JP2006528182A (ja) | 2006-12-14 |
| JP2006528182A5 true JP2006528182A5 (enExample) | 2011-02-17 |
Family
ID=34079415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521149A Pending JP2006528182A (ja) | 2003-07-18 | 2004-07-16 | 薬学的製剤および酸に起因する消化器疾患の治療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20050031700A1 (enExample) |
| EP (1) | EP1648417A4 (enExample) |
| JP (1) | JP2006528182A (enExample) |
| AR (1) | AR045061A1 (enExample) |
| AU (2) | AU2004257864A1 (enExample) |
| CA (1) | CA2531566C (enExample) |
| MX (1) | MXPA06000524A (enExample) |
| TW (1) | TWI337877B (enExample) |
| WO (1) | WO2005007117A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1747776A1 (en) * | 2005-07-29 | 2007-01-31 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising granular pantoprazole |
| US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
| AR056062A1 (es) | 2006-06-05 | 2007-09-19 | Bago Sa Labor | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
| US20070292534A1 (en) * | 2006-06-15 | 2007-12-20 | Dennis Nelson | Antacid and breath freshening composition |
| MX2009004475A (es) | 2006-10-27 | 2009-08-12 | Univ Missouri | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. |
| US20080166423A1 (en) * | 2007-01-06 | 2008-07-10 | Renjit Sundharadas | Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity |
| CN101980700A (zh) | 2008-02-20 | 2011-02-23 | 密苏里大学董事会 | 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法 |
| WO2012020279A1 (en) * | 2010-08-13 | 2012-02-16 | Compagnie Gervais Danone | Product for the upper gastric sphere |
| CN103230413A (zh) * | 2013-01-10 | 2013-08-07 | 沈阳亿灵医药科技有限公司 | 复方奥美拉唑制剂 |
| GB2513172A (en) * | 2013-04-18 | 2014-10-22 | Nupharm Lab Ltd | Liquid dosage form and delivery system |
| MA42806A (fr) * | 2015-05-29 | 2018-07-25 | Johnson & Johnson Consumer Inc | Utilisation d'un extrait d'agrume organique à haute capacité antimicrobienne et de xylitol en tant que système de conservation dans des liquides, des émulsions, des suspensions, des crèmes et des antiacides |
| JP6184656B1 (ja) * | 2015-10-13 | 2017-08-23 | テクノガード株式会社 | 胃腸管粘膜保護組成物 |
| WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| US11207307B2 (en) | 2016-06-16 | 2021-12-28 | Azurity Pharmaceuticals, Inc. | Composition and method for proton pump inhibitor suspension |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JP7069119B2 (ja) | 2016-08-11 | 2022-05-17 | アダミス ファーマシューティカルズ コーポレーション | 医薬組成物 |
| EP3720844A4 (en) | 2017-12-08 | 2021-08-11 | Adamis Pharmaceuticals Corporation | MEDICINAL COMPOSITIONS |
| GB2585628A (en) * | 2019-05-08 | 2021-01-20 | Alkaloid Ad | Pharmaceutical formulation |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| GB2631129A (en) | 2023-06-23 | 2024-12-25 | Orbit Pharma Ltd | A powder composition for oral suspension of proton pump inhibitors and the method of preparing the same |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148930B (enExample) * | 1977-09-19 | 1981-07-25 | Hoffmann La Roche | |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| SE8403179D0 (sv) * | 1984-06-13 | 1984-06-13 | Haessle Ab | New compounds |
| US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| JPH0643426B2 (ja) * | 1986-07-25 | 1994-06-08 | 東京田辺製薬株式会社 | イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 |
| SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
| US5215974A (en) * | 1986-11-21 | 1993-06-01 | Aktiebolaget Hassle | Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-acid secretion related diseases |
| US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| NZ224252A (en) * | 1987-04-21 | 1991-09-25 | Erba Carlo Spa | An anthracycline glycoside and its preparation |
| GB8809421D0 (en) * | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
| EP0425505B1 (en) * | 1988-06-30 | 1993-03-17 | The Upjohn Company | Transdermal antisecretory agents for gastrointestinal disease |
| SE8804629D0 (sv) * | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| SE8804628D0 (sv) * | 1988-12-22 | 1988-12-22 | Ab Haessle | New compounds |
| IE64199B1 (en) * | 1988-12-22 | 1995-07-12 | Haessle Ab | Compound with gastric acid inhibitory effect and process for its preparation |
| JP2694361B2 (ja) * | 1989-02-09 | 1997-12-24 | アストラ アクチエボラグ | 抗菌剤 |
| ES2066120T3 (es) * | 1989-02-10 | 1995-03-01 | Takeda Chemical Industries Ltd | Uso de derivados de bencimidazol como agentes antibacterianos. |
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| SE8903563D0 (sv) * | 1989-10-26 | 1989-10-26 | Haessle Ab | A novel dissolution system |
| US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| KR930000861B1 (ko) * | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
| SE9002043D0 (sv) * | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
| JP3049367B2 (ja) * | 1990-06-20 | 2000-06-05 | アストラゼネカ・アクチエボラーグ | ジアルコキシ−ピリジニル−ベンズイミダゾール誘導体、その製造方法およびそれを含む医薬 |
| WO1993006097A1 (en) * | 1991-09-20 | 1993-04-01 | Merck & Co., Inc. | Novel process for the preparation of anti-ulcer agents |
| TW224049B (enExample) * | 1991-12-31 | 1994-05-21 | Sunkyong Ind Ltd | |
| JPH05238938A (ja) * | 1992-02-28 | 1993-09-17 | Teikoku Seiyaku Co Ltd | スクラルファート懸濁液剤およびスクラルファートの投与方法 |
| IL105155A (en) * | 1992-04-24 | 1999-05-09 | Astra Ab | Combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
| US5504082A (en) * | 1992-06-01 | 1996-04-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridine compound and pharmaceutical compostions |
| FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
| SE9301489D0 (sv) * | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
| US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
| TW359614B (en) * | 1993-08-31 | 1999-06-01 | Takeda Chemical Industries Ltd | Composition containing benzimidazole compounds for rectal administration |
| US5935600A (en) * | 1993-09-10 | 1999-08-10 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing comestible unit and product therefrom |
| TW280770B (enExample) * | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
| US5714505A (en) * | 1994-01-05 | 1998-02-03 | Astra Aktiebolag | Method for treatment of psoriasis, by omeprazole or related compounds |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| GB9423968D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| HRP960232A2 (en) * | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
| PL326353A1 (en) * | 1995-10-17 | 1998-09-14 | Astra Pharma Prod | Pharmaceutically active quinozolinic compounds |
| JPH09157158A (ja) * | 1995-12-07 | 1997-06-17 | Takeda Chem Ind Ltd | 生薬配合製剤 |
| US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| ATE220543T1 (de) * | 1996-04-23 | 2002-08-15 | Janssen Pharmaceutica Nv | Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid |
| US6169102B1 (en) * | 1996-06-25 | 2001-01-02 | Takeda Chemical Industries, Ltd. | Oxazolone derivatives and their use as anti-Helicobacter pylori agent |
| US5766622A (en) * | 1996-08-14 | 1998-06-16 | The Procter & Gamble Company | Inhibiting undesirable taste in oral compositions |
| WO1998006385A1 (de) * | 1996-08-15 | 1998-02-19 | Losan Pharma Gmbh | Gut schluckbare orale arzneiform |
| US5885594A (en) * | 1997-03-27 | 1999-03-23 | The Procter & Gamble Company | Oral compositions having enhanced mouth-feel |
| ES2216351T3 (es) * | 1997-12-08 | 2004-10-16 | Altana Pharma Ag | Nueva forma de supositorio que comprende un compuesto activo labil o acidos. |
| US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| FR2774288B1 (fr) * | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| EP1004305B1 (en) * | 1998-04-20 | 2011-09-28 | Eisai R&D Management Co., Ltd. | Stabilized compositions containing benzimidazole-type compounds |
| US6319513B1 (en) * | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
| US6047829A (en) * | 1998-09-18 | 2000-04-11 | Westvaco Corporation | Unit dose packaging system (UDPS) having a child resistant locking feature |
| WO2000026185A2 (en) * | 1998-10-30 | 2000-05-11 | The Curators Of The University Of Missouri | Omeprazole solution and method of using same |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6239141B1 (en) * | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
| TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| AU5248900A (en) * | 1999-06-18 | 2001-01-09 | Takeda Chemical Industries Ltd. | Quickly disintegrating solid preparations |
| US6555139B2 (en) * | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| WO2001002389A1 (en) * | 1999-06-30 | 2001-01-11 | Takeda Chemical Industries, Ltd. | Crystals of benzimidazole compounds |
| JP2003504338A (ja) * | 1999-07-12 | 2003-02-04 | スミスクライン・ビーチャム・コーポレイション | 胸やけの処置法 |
| US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| US7678387B2 (en) * | 2000-06-06 | 2010-03-16 | Capricorn Pharma, Inc. | Drug delivery systems |
| US6572900B1 (en) * | 2000-06-09 | 2003-06-03 | Wm. Wrigley, Jr. Company | Method for making coated chewing gum products including a high-intensity sweetener |
| EP1334971A4 (en) * | 2000-10-12 | 2004-05-12 | Takeda Chemical Industries Ltd | BENZIMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF |
| US20040018239A1 (en) * | 2000-11-17 | 2004-01-29 | Hajime Ishida | Pharmaceutical preparation containing copolyvidone |
| US7285668B2 (en) * | 2000-12-01 | 2007-10-23 | Takeda Pharmaceutical Company Limited | Process for the crystallization of (R)- or (S)-lansoprazole |
| ES2403238T3 (es) * | 2000-12-07 | 2013-05-16 | Takeda Gmbh | Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido |
| WO2002051381A1 (en) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Porous substance and process for producing the same |
| US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| US20040097539A1 (en) * | 2001-03-28 | 2004-05-20 | Terashita Zen- Ichi | Hsp inductor |
| US6673936B2 (en) * | 2001-04-20 | 2004-01-06 | Linda B. Whittall | Process for purifying 6-methoxy omeprazole |
| US20020182270A1 (en) * | 2001-05-31 | 2002-12-05 | Stier Roger E. | Edible compositions comprising freeze-dried flavoring agents |
| ES2333645T3 (es) * | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros. |
| US20030050620A1 (en) * | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
| US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040006109A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040081671A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20040081700A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Dose titratable liquid dosage forms of acid labile drugs |
| JP4388331B2 (ja) * | 2002-10-25 | 2009-12-24 | オリンパス株式会社 | 発熱処置装置 |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| AR045062A1 (es) * | 2003-07-18 | 2005-10-12 | Santarus Inc | Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas |
| US8062664B2 (en) * | 2003-11-12 | 2011-11-22 | Abbott Laboratories | Process for preparing formulations of lipid-regulating drugs |
-
2004
- 2004-07-16 AR ARP040102531A patent/AR045061A1/es not_active Application Discontinuation
- 2004-07-16 JP JP2006521149A patent/JP2006528182A/ja active Pending
- 2004-07-16 MX MXPA06000524A patent/MXPA06000524A/es active IP Right Grant
- 2004-07-16 EP EP04778512A patent/EP1648417A4/en not_active Withdrawn
- 2004-07-16 CA CA2531566A patent/CA2531566C/en not_active Expired - Fee Related
- 2004-07-16 TW TW093121363A patent/TWI337877B/zh not_active IP Right Cessation
- 2004-07-16 WO PCT/US2004/023044 patent/WO2005007117A2/en not_active Ceased
- 2004-07-16 AU AU2004257864A patent/AU2004257864A1/en not_active Abandoned
- 2004-07-16 US US10/893,092 patent/US20050031700A1/en not_active Abandoned
-
2010
- 2010-07-30 US US12/847,938 patent/US20100297220A1/en not_active Abandoned
-
2011
- 2011-02-15 AU AU2011200642A patent/AU2011200642B2/en not_active Ceased
-
2014
- 2014-02-14 US US14/181,017 patent/US20140370104A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006528182A5 (enExample) | ||
| Uitdehaag et al. | A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets | |
| Turner et al. | Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones | |
| Digby et al. | Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders | |
| JP4860474B2 (ja) | Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素 | |
| Flacco et al. | Different β‐adrenoceptor subtypes coupling to cAMP or NO/cGMP pathways: implications in the relaxant response of rat conductance and resistance vessels | |
| Vives et al. | The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts | |
| Kuppens et al. | Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093) | |
| JP2009521931A5 (enExample) | ||
| Jia et al. | Bmp4-Msx1 signaling and Osr2 control tooth organogenesis through antagonistic regulation of secreted Wnt antagonists | |
| CY1123426T1 (el) | Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος | |
| DE602005021494D1 (de) | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung | |
| Hatcher et al. | Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation | |
| CA2496164A1 (en) | Benzimidazole quinolinones and uses thereof | |
| Schachter | Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers | |
| Wang et al. | Discovery of potent irreversible pan-fibroblast growth factor receptor (FGFR) inhibitors | |
| Carter et al. | Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors | |
| AU2022230312A1 (en) | Biomarkers for cancer therapy using mdm2 antagonists | |
| JP2009541387A5 (enExample) | ||
| Albrecht et al. | Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3 H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases | |
| Shimamoto | Glutamate transporter blockers for elucidation of the function of excitatory neurotransmission systems | |
| Rafiq et al. | Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats | |
| JP2003507380A5 (enExample) | ||
| EP3368052B1 (en) | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and genetic manipulation | |
| Carroll et al. | Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2 ‘-substituted-3 ‘-phenyl-5 ‘-pyridinyl)-7-azabicyclo [2.2. 1] heptanes. Novel nicotinic antagonist |